Symbols / HEPA $0.05 +19.05%
HEPA Chart
About
Hepion Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatment for hepatocellular carcinoma (HCC) and other chronic liver diseases in the United States. It develops Rencofilstat, a therapeutic drug candidate that binds and inhibits the function of a specific class of isomerase enzymes called cyclophilins that regulates protein folding, as well as preclinical experiments of Rencofilstat reflects decreased liver fibrosis; liver inflammation; liver tumor burden; and titers of HBV, HCV, HDV, and HIV-1. The company was formerly known as ContraVir Pharmaceuticals, Inc. and changed its name to Hepion Pharmaceuticals, Inc. in July 2019. Hepion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Morristown, New Jersey.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 581.01K |
| Enterprise Value | 192.62K | Income | -9.17M | Sales | — |
| Book/sh | 0.14 | Cash/sh | 0.20 | Dividend Yield | — |
| Payout | 0.00% | Employees | — | IPO | — |
| P/E | — | Forward P/E | -0.00 | PEG | — |
| P/S | — | P/B | 0.36 | P/C | — |
| EV/EBITDA | -0.04 | EV/Sales | — | Quick Ratio | 6.68 |
| Current Ratio | 10.77 | Debt/Eq | 6.45 | LT Debt/Eq | — |
| EPS (ttm) | -9.05 | EPS next Y | -11.43 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2024-04-16 16:00 | ROA | -72.99% |
| ROE | -6.28% | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 11.62M |
| Shs Float | 11.62M | Short Float | 4.10% | Short Ratio | 0.05 |
| Short Interest | — | 52W High | 5.00 | 52W Low | 0.03 |
| Beta | 1.94 | Avg Volume | 14.94K | Volume | 9.81K |
| Target Price | — | Recom | None | Prev Close | $0.04 |
| Price | $0.05 | Change | 19.05% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
—
Mean price target
2. Current target
$0.05
Latest analyst target
3. DCF / Fair value
$-3.52
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$0.05
Low
—
High
—
Mean
—
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2023-12-07 | down | Brookline Capital | Buy → Hold | — |
- Aug Outlook: How cyclical is Norfolk Southern Corporation (NFS) stock compared to rivals - CEO Change & Daily Technical Forecast Reports - Naître et grandir Sat, 07 Mar 2026 04
- Blood test aims to spot deadly liver cancer earlier in cirrhosis - Stock Titan ue, 03 Mar 2026 12
- Hepion Pharmaceuticals Initiates Transition to OTC Markets Following Nasdaq Delisting Notice - Nasdaq Mon, 12 May 2025 07
- Hepion Pharmaceuticals Announces Receipt of Delisting Notification from Nasdaq - Yahoo Finance Mon, 12 May 2025 07
- Can CADE stock attract ESG capital inflows - Weekly Loss Report & Reliable Breakout Stock Forecasts - Naître et grandir Sat, 07 Mar 2026 14
- Performance Recap: Can The Allstate Corporation Preferred Security continue delivering strong returns - Analyst Upgrade & Accurate Entry/Exit Alerts - baoquankhu1.vn hu, 05 Mar 2026 13
- HEPA Filters Manufacturers and Suppliers in the USA – A Thomas Industry Overview - Thomasnet Fri, 21 Nov 2025 08
- Best Vacuums for Allergy Sufferers - Consumer Reports Mon, 25 Aug 2025 07
- Hepion Pharmaceuticals (HEPA) Ends Merger with Pharma Two B - GuruFocus Wed, 09 Apr 2025 07
- Hepion Pharmaceuticals to be delisted from Nasdaq - Investing.com Nigeria Fri, 05 Dec 2025 08
- Hepion Pharmaceuticals Sells Rencofilstat Patent Assets - TipRanks Fri, 30 May 2025 07
- Hepion Pharmaceuticals Expands Market Presence: Multi-Disease Diagnostic Leader Debuts on OTCQB - Stock Titan Wed, 25 Jun 2025 07
- Hepion Pharmaceuticals Announces 1-for-50 Reverse Stock Split Effective March 17, 2025 - Nasdaq Mon, 17 Mar 2025 07
- Volume Report: What are the future prospects of IAC Inc - July 2025 Technicals & Safe Capital Allocation Plans - baoquankhu1.vn Fri, 06 Mar 2026 23
- Hepion Pharmaceuticals Announces Reverse Stock Split - Yahoo Finance Fri, 14 Mar 2025 07
Insider Transactions
No recent insider transactions.
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 815.53K | -32.54K | -93.18K | 0.00 |
| TaxRateForCalcs | 0.18 | 0.01 | 0.06 | 0.00 |
| NormalizedEBITDA | -19.32M | -45.19M | -43.54M | -30.32M |
| TotalUnusualItems | 4.43M | -4.07M | -1.46M | -2.31M |
| TotalUnusualItemsExcludingGoodwill | 4.43M | -4.07M | -1.46M | -2.31M |
| NetIncomeFromContinuingOperationNetMinorityInterest | -13.19M | -48.93M | -42.20M | -32.72M |
| ReconciledDepreciation | 30.76K | 67.13K | 77.46K | 86.07K |
| EBITDA | -14.88M | -49.26M | -45.00M | -32.63M |
| EBIT | -14.91M | -49.33M | -45.07M | -32.71M |
| NetInterestIncome | -1.25M | -9.46K | -10.16K | -8.86K |
| InterestExpense | 1.25M | 9.46K | 10.16K | 8.86K |
| NormalizedIncome | -16.81M | -44.89M | -40.84M | -30.41M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -13.19M | -48.93M | -42.20M | -32.72M |
| TotalExpenses | 19.35M | 45.26M | 43.62M | 30.40M |
| TotalOperatingIncomeAsReported | -19.35M | -48.45M | -45.49M | -30.40M |
| DilutedAverageShares | 122.89K | 79.42K | 76.23K | 70.29K |
| BasicAverageShares | 122.89K | 79.42K | 76.23K | 70.29K |
| DilutedEPS | -107.35 | -616.07 | -595.00 | -470.00 |
| BasicEPS | -107.35 | -616.07 | -595.00 | -470.00 |
| DilutedNIAvailtoComStockholders | -13.19M | -48.93M | -45.34M | -32.72M |
| NetIncomeCommonStockholders | -13.19M | -48.93M | -45.34M | -32.72M |
| OtherunderPreferredStockDividend | 0.00 | 3.14M | 0.00 | |
| PreferredStockDividends | 3.14M | |||
| NetIncome | -13.19M | -48.93M | -42.20M | -32.72M |
| NetIncomeIncludingNoncontrollingInterests | -13.19M | -48.93M | -42.20M | -32.72M |
| NetIncomeContinuousOperations | -13.19M | -48.93M | -42.20M | -32.72M |
| TaxProvision | -2.97M | -409.02K | -2.88M | 0.00 |
| PretaxIncome | -16.16M | -49.34M | -45.08M | -32.72M |
| OtherIncomeExpense | 4.43M | -4.07M | -1.46M | -2.31M |
| SpecialIncomeCharges | -3.17M | -3.19M | -1.87M | 0.00 |
| OtherSpecialCharges | 2.57M | |||
| WriteOff | 600.00K | 0.00 | ||
| ImpairmentOfCapitalAssets | 0.00 | 3.19M | 1.87M | 0.00 |
| GainOnSaleOfSecurity | 7.60M | -877.64K | 414.99K | -2.31M |
| NetNonOperatingInterestIncomeExpense | -1.25M | -9.46K | -10.16K | -8.86K |
| InterestExpenseNonOperating | 1.25M | 9.46K | 10.16K | 8.86K |
| OperatingIncome | -19.35M | -45.26M | -43.62M | -30.40M |
| OperatingExpense | 19.35M | 45.26M | 43.62M | 30.40M |
| ResearchAndDevelopment | 11.85M | 35.64M | 33.27M | 20.40M |
| SellingGeneralAndAdministration | 7.50M | 9.62M | 10.35M | 10.01M |
| GeneralAndAdministrativeExpense | 7.50M | 9.62M | 10.35M | 10.01M |
| OtherGandA | 7.50M | 9.62M | 10.35M | 10.01M |
| TotalRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| OperatingRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| PreferredSharesNumber | 87.27K | 87.27K | 87.38K | 1.81K |
| OrdinarySharesNumber | 139.17K | 96.37K | 76.23K | 76.22K |
| ShareIssued | 139.17K | 96.37K | 76.23K | 76.22K |
| NetDebt | 2.49M | |||
| TotalDebt | 2.90M | 209.02K | 53.61K | 316.99K |
| TangibleBookValue | -3.56M | 5.59M | 48.16M | 89.42M |
| InvestedCapital | -658.47K | 5.59M | 48.16M | 91.29M |
| WorkingCapital | -1.53M | 12.20M | 48.61M | 89.25M |
| NetTangibleAssets | -1.86M | 7.28M | 49.86M | 91.12M |
| CapitalLeaseObligations | 0.00 | 209.02K | 53.61K | 316.99K |
| CommonStockEquity | -3.56M | 5.59M | 48.16M | 91.29M |
| PreferredStockEquity | 1.70M | 1.70M | 1.70M | 1.70M |
| TotalCapitalization | -1.86M | 7.28M | 49.86M | 93.00M |
| TotalEquityGrossMinorityInterest | -1.86M | 7.28M | 49.86M | 93.00M |
| StockholdersEquity | -1.86M | 7.28M | 49.86M | 93.00M |
| GainsLossesNotAffectingRetainedEarnings | 8.35K | -78.78K | -90.17K | 0.00 |
| OtherEquityAdjustments | 8.35K | -78.78K | -90.17K | |
| RetainedEarnings | -237.82M | -224.63M | -175.70M | -133.50M |
| AdditionalPaidInCapital | 234.25M | 230.29M | 223.95M | 224.79M |
| CapitalStock | 1.70M | 1.70M | 1.70M | 1.71M |
| CommonStock | 14.00 | 10.00 | 381.00 | 7.62K |
| PreferredStock | 1.70M | 1.70M | 1.70M | 1.70M |
| TotalLiabilitiesNetMinorityInterest | 3.48M | 10.81M | 10.39M | 10.56M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 333.19K | 5.52M | 2.50M | 2.35M |
| OtherNonCurrentLiabilities | 1.63M | 2.09M | 1.89M | |
| DerivativeProductLiabilities | 333.19K | 3.80M | 0.00 | 0.00 |
| NonCurrentDeferredLiabilities | 0.00 | 409.02K | 409.02K | |
| NonCurrentDeferredTaxesLiabilities | 0.00 | 409.02K | 409.02K | |
| LongTermDebtAndCapitalLeaseObligation | 0.00 | 93.10K | 0.00 | 50.34K |
| LongTermCapitalLeaseObligation | 0.00 | 93.10K | 0.00 | 50.34K |
| CurrentLiabilities | 3.14M | 5.29M | 7.89M | 8.21M |
| OtherCurrentLiabilities | 386.00K | 366.23K | 2.99M | |
| CurrentDebtAndCapitalLeaseObligation | 2.90M | 115.92K | 53.61K | 266.65K |
| CurrentCapitalLeaseObligation | 0.00 | 115.92K | 53.61K | 266.65K |
| CurrentDebt | 2.90M | |||
| CurrentNotesPayable | 2.90M | 0.00 | ||
| PensionandOtherPostRetirementBenefitPlansCurrent | 0.00 | 1.91M | 1.64M | |
| PayablesAndAccruedExpenses | 243.89K | 4.79M | 5.56M | 3.31M |
| CurrentAccruedExpenses | 23.68K | 2.44M | 2.89M | 868.32K |
| Payables | 220.20K | 2.35M | 2.67M | 2.45M |
| TotalTaxPayable | 0.00 | |||
| AccountsPayable | 220.20K | 2.35M | 2.67M | 2.45M |
| TotalAssets | 1.61M | 18.09M | 60.24M | 103.55M |
| TotalNonCurrentAssets | -1.00 | 606.56K | 3.75M | 6.10M |
| OtherNonCurrentAssets | 364.19K | 426.17K | 583.33K | |
| GoodwillAndOtherIntangibleAssets | 0.00 | 3.19M | 1.87M | |
| OtherIntangibleAssets | 3.19M | 3.19M | ||
| Goodwill | 0.00 | 1.87M | ||
| NetPPE | -1.00 | 242.37K | 3.32M | 3.65M |
| AccumulatedDepreciation | -420.73K | -379.47K | -306.94K | -240.24K |
| GrossPPE | 420.73K | 621.83K | 3.63M | 3.89M |
| OtherProperties | 358.55K | 559.65K | 326.38K | 330.83K |
| MachineryFurnitureEquipment | 62.18K | 62.18K | 62.18K | 62.18K |
| BuildingsAndImprovements | 212.88K | 3.24M | 3.49M | |
| Properties | 0.00 | 0.00 | 0.00 | |
| CurrentAssets | 1.61M | 17.49M | 56.50M | 97.45M |
| PrepaidAssets | 1.21M | 2.70M | 5.31M | 6.10M |
| CashCashEquivalentsAndShortTermInvestments | 406.41K | 14.79M | 51.19M | 91.35M |
| CashAndCashEquivalents | 406.41K | 14.79M | 51.19M | 91.35M |
| CashFinancial | 406.41K | 14.79M | 51.19M | 91.35M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -18.22M | -40.90M | -34.98M | -31.35M |
| RepurchaseOfCapitalStock | 0.00 | -21.00M | 0.00 | |
| RepaymentOfDebt | 0.00 | -176.59K | ||
| IssuanceOfDebt | 0.00 | |||
| IssuanceOfCapitalStock | 2.50M | 0.00 | 17.86M | 82.15M |
| CapitalExpenditure | -14.30K | -16.34K | -130.41K | |
| InterestPaidSupplementalData | 0.00 | 0.00 | 941.00 | 2.02K |
| EndCashPosition | 406.41K | 14.79M | 51.19M | 91.35M |
| BeginningCashPosition | 14.79M | 51.19M | 91.35M | 40.73M |
| EffectOfExchangeRateChanges | 87.12K | 5.02K | -47.14K | 0.00 |
| ChangesInCash | -14.47M | -36.41M | -40.11M | 50.62M |
| FinancingCashFlow | 4.35M | 4.49M | -5.14M | 81.98M |
| CashFlowFromContinuingFinancingActivities | 4.35M | 4.49M | -5.14M | 81.98M |
| NetOtherFinancingCharges | -2.00M | |||
| ProceedsFromStockOptionExercised | 1.85M | 4.49M | 0.00 | 0.00 |
| NetPreferredStockIssuance | 0.00 | -3.14M | 0.00 | |
| PreferredStockPayments | 0.00 | -21.00M | 0.00 | |
| PreferredStockIssuance | 0.00 | 17.86M | 0.00 | |
| NetCommonStockIssuance | 2.50M | 0.00 | 0.00 | 82.15M |
| CommonStockIssuance | 2.50M | 0.00 | 0.00 | 82.15M |
| NetIssuancePaymentsOfDebt | 0.00 | -176.59K | ||
| NetLongTermDebtIssuance | 0.00 | -176.59K | ||
| LongTermDebtPayments | 0.00 | -176.59K | ||
| LongTermDebtIssuance | 0.00 | |||
| InvestingCashFlow | -600.00K | -14.30K | -14.07K | -130.41K |
| CashFlowFromContinuingInvestingActivities | -600.00K | -14.30K | -14.07K | -130.41K |
| NetOtherInvestingChanges | -600.00K | |||
| NetPPEPurchaseAndSale | 0.00 | -14.30K | -14.07K | -130.41K |
| SaleOfPPE | 0.00 | 2.27K | 0.00 | |
| PurchaseOfPPE | 0.00 | -14.30K | -16.34K | -130.41K |
| OperatingCashFlow | -18.22M | -40.89M | -34.96M | -31.22M |
| CashFlowFromContinuingOperatingActivities | -18.22M | -40.89M | -34.96M | -31.22M |
| ChangeInWorkingCapital | -2.68M | 2.97M | 3.15M | -5.57M |
| ChangeInOtherWorkingCapital | 252.80K | |||
| ChangeInOtherCurrentLiabilities | -209.02K | -96.71K | -263.38K | -258.59K |
| ChangeInOtherCurrentAssets | 212.88K | 89.83K | 253.10K | 252.80K |
| ChangeInPayablesAndAccruedExpense | -4.55M | 302.92K | 2.25M | -1.07M |
| ChangeInPrepaidAssets | 1.86M | 2.68M | 917.31K | -4.49M |
| OtherNonCashItems | 1.82M | -440.00K | -414.99K | 2.31M |
| StockBasedCompensation | 791.64K | 1.34M | 2.55M | 4.67M |
| AssetImpairmentCharge | 600.00K | 3.19M | 1.87M | 0.00 |
| DeferredTax | 0.00 | -409.02K | 0.00 | |
| DeferredIncomeTax | 0.00 | -409.02K | 0.00 | |
| DepreciationAmortizationDepletion | 30.76K | 67.13K | 77.46K | 86.07K |
| DepreciationAndAmortization | 30.76K | 67.13K | 77.46K | 86.07K |
| Depreciation | 30.76K | 67.13K | ||
| OperatingGainsLosses | -5.58M | 1.32M | ||
| GainLossOnInvestmentSecurities | -5.58M | 1.32M | ||
| NetIncomeFromContinuingOperations | -13.19M | -48.93M | -42.20M | -32.72M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for HEPA
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|